1998, volume 14, issue 1


Zopiklon u pacjentów leczonych ambulatoryjnie z powodu bezsenności

Tomasz Zyss, Adam Szymusik
Farmakoterapia w Psychiatrii i Neurologii, 1998, 1,135-144

Clinical assessment of Imovane was examined in the sample of 50 out-patients treated for sleeplessness. The treatment lasted three weeks; the only, evening dose of the medicine 7.5 mg was applied.
Imovane showed marked influence on sleep measured by score reduction of Sleep Disorder Intensity Scale. Most effectively it impacted the sleep latency (shortened it), and it was less effective while influencing on shortened by illness sleep duration. Additionally Imovane was more efficient in younger patients and in those patients with short period of sleeplessness reported. Majority of patients tolerated the medicine very well; in 42 no side effects were present. The most frequent side effect was the feeling of bitter, metallic taste in mouth, vertigo and nausea (8-10% of all investigated). The intensity of side effects was low; there was no need to include some additional treatment, or to stop the treatment.